VanEck US Equity Buffer ETF - October

30.75

+0.09430.31%

Volume:15.01K

Turnover:461.66K

Market Cap:614.90K

PE:- -

High:30.78

Open:30.73

Low:30.67

Close:30.65

52wk High:32.83

52wk Low:30.51

Shares:20.00K

Float Shares:20.00K

Volume Ratio:0.98

T/O Rate:75.05%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema

GlobeNewswire

·

Oct 02

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/OCT"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OCT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OCT\",,,,,undefined,":{"symbol":"OCT","market":"US","secType":"STK","nameCN":"VanEck US Equity Buffer ETF - October","latestPrice":30.745,"timestamp":1791230400000,"preClose":30.6507,"halted":0,"volume":15009,"delay":0,"changeRate":0.0030766018394359834,"floatShares":20000,"shares":20000,"eps":0,"marketStatus":"Pre-Mkt","change":0.0943,"latestTime":"10-06 07:03:57 EDT","open":30.73,"high":30.78,"low":30.67,"amount":461655.52722,"amplitude":0.003589,"askPrice":48.88,"askSize":100,"bidPrice":12.37,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791293400000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":30.745,"postHourTrading":{"tag":"盘后","latestPrice":30.76,"preClose":30.745,"latestTime":"19:30 EDT","volume":6,"amount":184.47,"timestamp":1791243001982,"change":0.015,"changeRate":0.000488,"amplitude":0},"volumeRatio":0.9801795796745064},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OCT\",,,,,undefined,":{"symbol":"OCT","floatShares":20000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.9801795796745064,"shares":20000,"dividePrice":0,"high":30.78,"amplitude":0.003589,"preClose":30.6507,"low":30.67,"week52Low":30.5094,"pbRate":"--","week52High":32.83,"institutionHeld":0,"latestPrice":30.745,"eps":0,"divideRate":0,"volume":15009,"delay":0,"ttmEps":0,"open":30.73,"prevYearClose":30.68,"prevWeekClose":30.6507,"prevMonthClose":30.68,"prevQuarterClose":30.68},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OCT\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OCT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OCT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OCT\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672112037","title":"Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema","url":"https://stock-news.laohu8.com/highlight/detail?id=2672112037","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672112037?lang=en_us&edition=fundamental","pubTime":"2026-10-02 20:00","pubTimestamp":1790942400,"startTime":"0","endTime":"0","summary":"First patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/02/3373778/0/en/surrozen-announces-fda-clearance-of-ind-application-for-szn-8141-for-the-treatment-of-diabetic-macular-edema.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4575","BK4532","LU2458330169.SGD","AMDY","SMH","AMDD","BAI","FTXL","AMUU","SOXY","LABU","AMDL","USXF","QQQA","FAI","CHPS","GAMR","OCT","ARTY","AMDG","TRFK","DAMD","AMDU","IND","AMD","LU1861559042.SGD","LU1861220033.SGD","AIS","IETC","AMDW","SMHX","SOXX","WUGI","ILDR","XNTK","AMYY","BK4529","AMDS","CHAT","TTEQ","SAMD0main","AMDC","LU2461242641.AUD","AIQ","PSI","CNAV","TEK","WISE","IE00BMPRXQ63.HKD","LEGR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/OCT\",params:#limit:6,delay:false,,,undefined,":[]}}